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Abstract
Background: Cryopyrin-associated periodic syndrome (CAPS) is a group of rare autoinflammatory diseases, and
of these, chronic infantile neurologic, cutaneous, and articular/neonatal-onset multisystem inflammatory disease
(CINCA/NOMID) syndrome has the most severe phenotype. Canakinumab, a monoclonal antibody that targets
interleukin-1β, has been shown to be an effective treatment for resolving systemic inflammation. However, its
efficacy for treating ophthalmic symptoms of this disorder remains unclear.
Findings: A 64-year-old female reported episodes of nonpruritic urticaria, fever, aseptic meningitis, and bilateral
sensorineural deafness. Her son had experienced similar symptoms. She was initially referred for ophthalmologic
treatment for an infectious corneal ulcer. Examination of her right eye by slit lamp biomicroscopy showed diffuse
conjunctival injection, corneal infiltrates, a corneal ulcer, and hypopyon. She was therefore treated aggressively with
topical and systemic antibiotics in addition to antifungal medications. However, this was ineffective. Genetic analysis
detected the heterozygous germline p.Asp303Asn mutation in the NLRP3 gene in both our patient and her son.
She was therefore diagnosed with CINCA/NOMID syndrome based on her clinical manifestations. All of the patient’s
physical and ophthalmic symptoms were resolved within a few days after the initiation of canakinumab treatment.
During an 18-month follow-up period, no adverse events or severe infections were observed.
Conclusions: Our case report indicates that canakinumab is effective not only for the treatment of systemic
inflammation but also for treating ophthalmic involvement, such as recurrent stromal keratitis and anterior uveitis.
Keywords: Cryopyrin-associated periodic syndrome, Chronic infantile neurologic, Cutaneous and articular/
neonatal-onset multisystem inflammatory disease syndrome, Canakinumab, Stromal keratitis, Uveitis
Findings
Background
Cryopyrin-associated periodic syndrome (CAPS) is an
autoinflammatory disorder caused by heterozygous muta-
tions in the NLRP3 gene and include three distinct condi-
tions, namely familial cold autoinflammatory syndrome,
Muckle-Wells syndrome, and chronic infantile neurologic,
cutaneous, and articular (also known as neonatal-onset
multisystem inflammatory disease) (chronic infantile
neurologic, cutaneous, and articular/neonatal-onset
multisystem inflammatory disease (CINCA/NOMID))
syndrome [1–5]. Gain-of-function mutations in NLRP3
result in the excessive production of the potent proin-
flammatory cytokine interleukin-1β (IL-1β), thereby
evoking the autoinflammatory manifestations of CAPS
[6–8]. CINCA/NOMID syndrome is the most severe
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CAPS phenotype [9, 10]. The eye manifestations are pleio-
tropic in patients with CINCA/NOMID syndrome, with
inflammation involving the cornea, sclera, anterior cham-
ber, vitreous, retina, and optic disc [11]. Canakinumab, a
fully humanized monoclonal antibody that selectively
blocks IL-1β, has been shown to be an effective treatment
for CINCA/NOMID syndrome [12–14]. However, the
efficacy of canakinumab in treating its ophthalmic mani-
festations remains unclear.
Here, we describe a case of an adult female with
CINCA/NOMID syndrome-related stromal keratitis and
uveitis, which was successfully treated with canakinumab.
Case presentation
A 64-year-old female was referred to our department for
the treatment of an infectious corneal ulcer. She re-
ported experiencing daily episodes of urticaria-like
rashes, fevers, and arthralgia since birth. She also had a
history of meningitis, which showed no evidence of
infection and did not respond to antibiotic treatment,
and bilateral sensorineural deafness since high school.
The patient had been evaluated for collagen diseases
many times at other hospitals, but no disease-specific
autoantibodies had been detected. Her detailed ophthal-
mic history was unclear. Her family history was signifi-
cant in that her son had displayed similar symptoms
from birth that had been treated with corticosteroids
and immunosuppressants.
At the patient’s initial visit, a clinical examination
confirmed the presence of a rash on her body with a
saddle nose and clubbed fingers. Biological inflamma-
tory markers, including the white blood cell count and
C-reactive protein (CRP) level, were high. The patient’s
visual acuity was 20/400 in the right eye and 20/22 in
the left eye, and the intraocular pressure was 11 mmHg
in both eyes. Slit lamp biomicroscopy of the right pseu-
dophakic eye showed diffuse conjunctival injection,
pterygium-like corneal invasion of the conjunctival
tissue, and the presence of corneal infiltrates with
epithelial erosion (Fig. 1a). Marked cell and flare with
hypopyon were also present in the anterior chamber of
the right eye. An opening existed from previous laser
iridectomy. The details of the right fundus were
obscured by corneal opacity and anterior inflammation.
Although the anterior segment of the left pseudophakic
eye was normal, a fundus examination showed a pale
optic disc, sheathing of the retinal arteries, and yellow-
ish deposits in the posterior pole (Fig. 1b, c).
Based on the observations above, we considered the
possibility of a corneal bacterial and/or fungal infection.
The patient was therefore treated with topical and
systemic antibiotics (eyedrops containing 0.5 % levoflox-
acin, 0.3 % gatifloxacin, 0.5 % cefmenoxime, and 0.3 %
gentamicin and intravenous flomoxef at 2 g/day) and
Fig. 1 Initial examination of a 64-year-old female referred with ulcerative
keratitis and anterior chamber inflammation. a Slit lamp biomicroscopy
of the anterior segment of the right pseudophakic eye (visual
acuity 20/400) showed diffuse conjunctival injection, pterygium-like
corneal invasion of the conjunctival tissue, and the presence of corneal
infiltrates with epithelial erosion (arrowhead). Marked cells and flares
with hypopyon (arrows) were also present in the anterior chamber of
the right eye. b Slit lamp biomicroscopy of the anterior segment of the
left pseudophakic eye (visual acuity 20/22) appeared normal. c Fundus
examination of the left eye showed a pale optic disc, sheathing of the
retinal arteries (arrowheads) and yellowish deposits in the posterior
pole (arrows)
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also with antifungal drugs (1 % pimaricin ointment and
oral itraconazole at 200 mg/day). She received these
medications as well as topical corticosteroid therapy
(0.1 % betamethasone and 0.1 % fluorometholone
eyedrops) for 9 months. However, this did not com-
pletely resolve the problem and repeated exacerbations
of anterior inflammation with ulcerative keratitis contin-
ued. During the course of this treatment, we carried out
microbiological investigations of corneal scrapes, viro-
logical investigations for varicella zoster, herpes simplex
virus, and cytomegalovirus in the aqueous humor and
tests for HLA-B51. However, all tests were negative.
During this period, the patient experienced one episode
of aseptic meningitis (Fig. 2). In addition, the urticaria-
like rash on her body persisted and her CRP level
remained elevated.
The presence of the urticaria-like rash, fever, arthral-
gia, and both her past history and her family history
led us to consider a CAPS diagnosis. Therefore, a gen-
etic analysis was carried out, and this detected a
heterozygous, germline p.Asp303Asn mutation in the
NLRP3 gene in both the patient and her son, confirm-
ing a diagnosis of CAPS. Based on her severe physical
and ophthalmic manifestations, including chronic
meningitis and posterior segment involvement in the
left eye, a diagnosis of CINCA/NOMID syndrome was
made. The patient was therefore started on a course of
150 mg canakinumab (Ilaris; Novartis Pharma AG,
Basel, Switzerland) given subcutaneously once every
6 weeks. All of the patient’s physical symptoms (rash,
arthralgia, aseptic meningitis, and fever) and ophthalmic
symptoms (conjunctival injection, ulcerative keratitis,
anterior chamber inflammation, and hypopyon) resolved
within a few days. In addition, the patient’s CRP level
normalized and stabilized (Fig. 2).
After the anterior inflammation had resolved, we
conducted a fundus examination, which showed that
the right eye was more severely affected than the left
eye, with a pale optic disc, peripapillar sheath-like
fibrosis involving the retinal vessels, and yellowish
deposits in the mid-periphery (Fig. 3a, b). Spectral-
domain optical coherence tomography (Cirrus; Carl
Zeiss Meditec Inc., Dublin, CA) showed an intact
ellipsoid zone and drusen-like subretinal deposits
internal to the retinal pigment epithelium (Fig. 3c). At
the patient’s last visit, which was 18 months after the
first treatment with canakinumab, her visual acuity was
20/66 in the right eye and 20/20 in the left eye and slit
lamp biomicroscopy showed no sign of anterior inflam-
mation in the right eye. No adverse events had been
documented during the follow-up period.
Discussion
In this report, we have described a case of CINCA/
NOMID syndrome-related stromal keratitis and uve-
itis in an adult female, which was successfully treated
with canakinumab. To the best of our knowledge, this
is the first report of CINCA/NOMID syndrome,
which describes the ophthalmic findings before and
after the canakinumab treatment in detail. In most of
the previous reports describing the efficacy of canaki-
numab in patients with CAPS, conjunctivitis has been
the only end point used to assess ocular manifesta-
tions [13, 15]. Therefore, the efficacy of canakinumab
for a variety of ophthalmic symptoms had remained
unclear. In the patient we have described in this
report, we found that canakinumab therapy led to a
marked improvement, not only in systemic inflamma-
tion but also in ophthalmic manifestations such as
recurrent stromal keratitis and anterior uveitis. We
were surprised that the subcutaneous injection of
canakinumab resolved the ophthalmic inflammation
so dramatically, in spite of the presence of blood-
retina and blood-aqueous barriers in the eye. Canaki-
numab has been reported to induce adverse events,
such as nasopharyngitis, upper respiratory infections,
and gastroenteritis, presumably due to the effects of
blocking the actions of the proinflammatory cytokine
IL-1β [13, 15]. However, no side effects were observed
during the follow-up period in this case. Further
observation will be needed to check the long-term
efficacy of canakinumab.
Fig. 2 Schematic representation showing clinical course and
treatment regime. Duration of medication (open bars) and patient’s
symptoms (closed bars) showing that after initiating canakinumab
therapy (arrows), all physical symptoms (rash, arthralgia, aseptic
meningitis, and fever) and ophthalmic symptoms (conjunctival
injection, ulcerative keratitis, anterior chamber inflammation, and
hypopyon) were resolved within a few days. In addition, the level of
C-reactive protein (CRP) normalized and stabilized. No recurrence or
adverse events were observed during a follow-up period
of 18 months
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This case indicates that it is important to make a
diagnosis and start treatment with canakinumab as
early as possible to prevent irreversible ocular compli-
cations. In our patient, the visual acuity of the right
eye did not completely recover, as the delay in diag-
nosis resulted in post-inflammatory optic disc atrophy
and stromal opacification. It has been only 13 years
since the mutation of CIAS1 was discovered in CAPS
patient. Although the discovery has made much
progress in pathophysiologic and therapeutic under-
standing of CAPS, clear diagnostic criteria have not
been yet established. In addition, CAPS is a very rare
disease; for example, CINCA/NOMID syndrome has a
prevalence of 1/4,000,000 in Japan [16]. These condi-
tions can cause our lack of awareness of the disease,
resulting in delayed diagnosis and treatment. We
think it is important to consider CAPS including
CINCA/NOMID syndrome in the differential diagnosis
for patients who present with periodic fever, urticaria-
like rashes, meningitis, articular manifestations, and
ocular inflammation.
In conclusion, our case report indicates canakinu-
mab is effective in CINCANOMID syndrome, not
only for systemic inflammation but also for ophthal-
mic involvement, such as recurrent stromal keratitis
and anterior uveitis. Further prospective studies will
be required to determine the efficacy of canakinu-
mab, including as many patients as possible with this
rare disease.
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Written informed consent was obtained from the
patient for publication of this case report and accom-
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journal.
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Fig. 3 Ophthalmic findings in the right eye after canakinumab
therapy. a Anterior inflammation (conjunctival injection, ulcerative
keratitis, anterior chamber inflammation, and hypopyon) remained
resolved 6 months after the initiation of canakinumab therapy.
b Fundus examination of the right eye showed a pale optic disc
with peripapillar sheath-like fibrosis involving the retinal vessels
(arrowhead) and yellowish deposits in the posterior pole (arrows).
c Spectral-domain optical coherence tomography showed intact
ellipsoid zone and drusen-like subretinal deposits (arrows) internal to
the retinal pigment epithelium
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